MOUD Buprenorphine Subli denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issued This Denial

Aetna applies quantity limits (QL) to sublingual buprenorphine for MOUD — restricting the number of units covered per fill or per month. When a prescriber orders a quantity above Aetna's limit, the pharmacy system automatically rejects the claim. This is extremely common and does not reflect a clinical judgment that the prescribed quantity is inappropriate; it is an automated policy threshold.

Federal MHPAEA parity law is directly relevant here: quantity limits applied to MOUD medications must be no more restrictive than quantity limits applied to comparable drugs used for other chronic medical or surgical conditions. If Aetna cannot demonstrate that it applies equivalent QL scrutiny to analogous treatments, the limit may be challengeable on parity grounds.

## Why This Denial Is Appealable

Quantity-limit denials are overturned when the clinical record demonstrates a documented medical reason the prescribed quantity is necessary — for example, stabilization dosing, divided dosing schedules, or a prescribing approach supported by the FDA label and applicable clinical guidelines from organizations such as SAMHSA or the applicable addiction medicine society. Your prescriber's letter is the cornerstone of this appeal.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline on the denial letter. Aetna must respond within 30 days (standard) or 72 hours (urgent).
• External review (ACA §2719 / ERISA §503): Available after exhausting internal appeals — generally within four months of the final internal denial. An independent IRO determines whether the quantity limit, as applied to your case, is consistent with generally accepted medical standards.
• Expedited review: Request if standard timelines would jeopardize your treatment stability.

## Concrete Appeal Steps

1. Obtain Aetna's quantity-limit policy for the specific sublingual buprenorphine product — the exact number of units allowed per period. 2. Ask your prescriber to document in a medical-necessity letter why the prescribed quantity is clinically indicated, citing the FDA-approved prescribing label's dosing guidance and any applicable SAMHSA or specialty-society clinical practice guideline. 3. Include chart notes supporting the clinical rationale (e.g., clinical assessment, treatment progress notes). 4. If applicable, include a MHPAEA argument requesting Aetna's comparative data showing how QL is applied to analogous medical conditions. 5. Pursue external review if the internal appeal is denied.

## Documentation to Gather

• Aetna's quantity-limit policy document for this drug
• Prescriber's letter explaining the medical necessity of the prescribed quantity
• FDA prescribing label confirming the dosing range the prescription falls within
• Chart notes documenting clinical rationale for the quantity
• Prior fill history if the quantity was previously covered
• MHPAEA comparative-benefit request (optional but powerful)

## Criteria-Mapping Structure

Map the clinical record to Aetna's stated criteria:

| Aetna Quantity-Limit Requirement | Supporting Evidence | |---|---| | Quantity within policy limit OR exception criteria met | Prescriber letter explaining medical necessity of prescribed quantity | | Dose consistent with FDA label range | FDA label dosing section + prescriber letter | | Clinical rationale documented | Chart notes from treating clinician |